CHE
Chemed Corporation
CHE's fundamentals are mixed: it turned 11% of its revenue into free cash flow. At 26x earnings, it's trading in line with its usual 29x. Analysts expect earnings growth.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
CHE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Stable | |
| Healthy |
CHE's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
CHE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 20x | $550 | — |
| Cheap | 24x | $500 | -9.2% |
| Current | 26x | $550 | — |
| Fair | 29x | $602 | +9.5% |
| Expensive | 34x | $710 | +29% |
Historical ranges are pointers, not guarantees.
CHE's PE is in its cheap range at 26x. If earnings grow as analysts expect, today's price would be 20x next year's earnings.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
CHE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
CHE has the edge over HIMS on the outlook, with more favorable earnings expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
CHE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $27.06 | +30% |
| Q3 2026 | $20.87 | +10% |
| Q2 2026 | $19.88 | +2.3% |
| Q1 2026 | $18.32 | -11% |
| Q4 2025 | $18.34 | -7.8% |
| Q3 2025 | $18.89 | -4.6% |
| Q2 2025 | $19.43 | -1.5% |
| Q1 2025 | $20.51 | +10% |
| Q4 2024 | $19.89 | +11% |
CHE has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
CHE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $690.9M | +11% |
| Q2 2026 | $673.3M | +8.8% |
| Q1 2026 | $657.5M | +1.6% |
| Q4 2025 | $639.3M | -0.1% |
| Q3 2025 | $624.9M | +3.1% |
| Q2 2025 | $618.8M | +3.8% |
| Q1 2025 | $646.9M | +9.8% |
| Q4 2024 | $640M | +9.2% |
CHE's revenue is growing: $691M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +2 points |
| Q2 2026 | 13% | +2.3 points |
| Q1 2026 | 13% | -1.8 points |
| Q4 2025 | 16% | -2 points |
| Q3 2025 | 12% | -3.2 points |
| Q2 2025 | 11% | -3.8 points |
| Q1 2025 | 15% | +2.4 points |
| Q4 2024 | 18% | -1.2 points |
CHE has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over CHE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
CHE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $37.9M | -43% |
| Q2 2026 | $69.3M | -44% |
| Q1 2026 | $71.1M | +265% |
| Q4 2025 | $117.2M | -23% |
| Q3 2025 | $65.9M | -14% |
| Q2 2025 | $122.8M | +85% |
| Q1 2025 | $19.5M | -73% |
| Q4 2024 | $152.2M | +57% |
CHE's free cash flow has been positive every quarter for seven years: $295M over the past year, down 18% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over CHE on cash flow, with more consistent year-over-year improvement.
CHE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.5% | -64K shares |
| 1 year | -8.8% | -1.3M shares |
| 3 years | -14% | -2.1M shares |
| 5 years | -17% | -2.7M shares |
| Available history | -21% | -3.4M shares |
CHE has the edge over HIMS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $62.5M |
| Q2 2026 | $97.5M |
| Q1 2026 | $190M |
| Q4 2025 | $174.6M |
| Q3 2025 | $180.8M |
| Q2 2025 | $42.9M |
| Q1 2025 | $33.2M |
| Q4 2024 | $209.3M |
CHE spent $525M buying back its own shares over the past year, up 13% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has 234M diluted shares, down 6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
CHE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.4x | Very low |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 0.2x | Very low |
| Q4 2025 | -0.2x | Net Cash |
| Q3 2025 | -0.3x | Net Cash |
| Q2 2025 | -0.6x | Net Cash |
| Q1 2025 | -0.4x | Net Cash |
| Q4 2024 | -0.4x | Net Cash |
CHE's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
CHE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.7 | Neutral |
| Stochastic | 65.1 | Neutral |
CHE's weekly RSI is 66 (neutral) and its Stochastic is 65 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
CHE PE vs Healthcare Sector
| Metric | CHE | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 26x | 2% above |
| PE % | 32 | 29 | 3 pts above |
CHE is trading at 26x earnings, in line with the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
CHE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $519.7 | 5.9% above |
| 20 week MA | $518.9 | 6% above |
| 50 week MA | $462.7 | 19% above |
| 100 week MA | $488.0 | 13% above |
| 200 week MA | $523.0 | 5.2% above |
CHE has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
CHE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $438.7 | $536.7 | +22% |
| 2021 | $536.7 | $525.3 | -2.1% |
| 2022 | $525.3 | $516.2 | -1.7% |
| 2023 | $516.2 | $584.8 | +13% |
| 2024 | $584.8 | $522.8 | -11% |
| 2025 | $522.8 | $432.2 | -17% |
| 2026 YTD | $432.2 | $550.2 | +27% |
CHE has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.